Showing posts with label LCA. Show all posts
Showing posts with label LCA. Show all posts

Wednesday, October 21, 2020

Study reveals significant restoration of retinal and visual function following Gene Therapy

(c) Nature Biomedical Engg
A breakthrough study, led by researchers from the University of California, Irvine, has demonstrated restoration of retinal and visual functions of mice models suffering from inherited retinal disease.

Published today in Nature Biomedical Engineering, the paper, titled, “Restoration of visual function in adult mice with an inherited retinal disease via adenine base editing,” illustrates the use of a new generation CRISPR technology and lays the foundation for the development of a new therapeutic modality for a wide range of inherited ocular diseases caused by different gene mutations.

Tuesday, December 18, 2018

Injection Improves Vision in a Form of Childhood Blindness

(c) NIH
A new treatment for patients with a form of congenital retinal blindness has shown success in improving vision, according to results published today in Nature Medicine led by researchers at the Scheie Eye Institute  in the Perelman School of Medicine at the University of Pennsylvania.

Sunday, March 25, 2018

LCA patients gain benefit from Spark Therapeutics' gene therapy treatment, Luxturna

(c) Mass Eye & Ear
With the approval of Spark Therapeutics' Luxturna for Leber's Congenital Amaurosis (LCA), eye institutions around the US have started offering the treatment to their patients. In recent days, we have heard of this treatment being offered for the first time after the approval in Massachusetts Eye and Ear in Boston, followed the same day by the Children's Hospital of Los Angeles. A few days later, Bascom Palmer Eye Institute completed its first case.

Friday, May 15, 2015

Researchers discover new forms of retinal blindness

Scientists from the University of Leeds have discovered six new forms of inherited blindness, each one resulting from mutations in a different gene important in eye development and vision.